Abstract
Category:
Ankle Arthritis
Introduction/Purpose:
The purpose of this systematic review and meta-analysis was to compare the volume of blood loss, transfusion rates and complication rates between patients who were administered tranexamic acid (TXA) versus patients who were not administered TXA during total ankle arthroplasty (TAA).
Methods:
During January 2023, the PubMed, Embase and Cochrane library databases were systematically reviewed to identify clinical studies comparing outcomes between patients who were administered TXA versus patients who were not administered TXA during TAA. Data regarding surgical characteristics, subjective clinical outcomes, total blood loss, intra-operative blood loss, total complications and wound complications rates were extracted and analysed. In total, 5 comparative clinical studies were included in this review.
Results:
194 patients received TXA and 187 patients did not receive TXA during TAA. There was a statistically significant reduced volume of total blood loss in favor of patients who received TXA compared to patients who did not receive TXA during TAA (SMD:-0.7832; p< 0.0001). A statistically significant reduced volume of intra-operative blood loss between the TXA cohort and the control cohort was also observed in favor of the TXA cohort (SMD:-1.14; p< 0.0001]. A statistically significant reduced volume of hemoglobin loss was found in favor of patients who received TXA compared to the control cohort (SMD: -0.9548; p< 0.02). A higher transfusion rate was found in the control cohort (1.1%) compared to the TXA cohort. No difference in complication rates was observed between the cohorts.
Conclusion:
This systematic review and meta-analysis found that patients who received peri-operative TXA had statistically significant reduced total blood volume loss, intra-operative blood volume loss, hemoglobin loss together with no statistically significant difference in complication rates following TAA. Further randomised control trials with improved data collection are necessary to elucidate the optimal dosage, frequency and role of TXA in the peri-operative setting for TAA.
